Inhibitory effects of tacrine and physostigmine on catecholamine secretion and membrane currents in guinea‐pig adrenal chromaffin cells
暂无分享,去创建一个
S. Ito | T. Sugawara | T. Ohta | Y. Nakazato | N. Kitamura
[1] S. Ito,et al. Calcium channel subtypes in porcine adrenal chromaffin cells , 1997, Pflügers Archiv.
[2] S. Ito,et al. Tacrine inhibits nicotinic secretory and current responses in adrenal chromaffin cells. , 1997, European Journal of Pharmacology.
[3] Manuela G. López,et al. Q‐ and L‐type Ca2+ channels dominate the control of secretion in bovine chromaffin cells , 1994, FEBS letters.
[4] M. Reuben,et al. Blockade of nicotinic responses by physostigmine, tacrine and other cholinesterase inhibitors in rat striatum , 1994, British journal of pharmacology.
[5] B. Sahakian,et al. Tetrahydroaminoacridine (THA) in Alzheimer's disease: An assessment of attentional and mnemonic function using CANTAB , 1993, Acta neurologica Scandinavica. Supplementum.
[6] C. Forray,et al. Effects of tacrine on brain muscarinic-receptor-mediated second-messenger signals. , 1993, Pharmacology.
[7] R. Gross,et al. Tetrahydroaminoacridine (THA) reduces voltage-dependent calcium currents in rat sensory neurons , 1991, Neuroscience Letters.
[8] E. El-Fakahany,et al. Muscarinic subtype selectivity of tetrahydroaminoacridine: possible relationship to its capricious efficacy. , 1991, European journal of pharmacology.
[9] D. Mash,et al. Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine. , 1989, The Journal of pharmacology and experimental therapeutics.
[10] B. Winblad,et al. Effects of THA on ionic currents in myelinated axons of Xenopus laevis. , 1989, European journal of pharmacology.
[11] J. C. Lodder,et al. 9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current. , 1987, European journal of pharmacology.
[12] A. Kling,et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. , 1986, The New England journal of medicine.
[13] R. Tsien,et al. Calcium rises abruptly and briefly throughout the cell at the onset of anaphase. , 1986, Science.
[14] E. Albuquerque,et al. The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex. , 1985, Molecular pharmacology.
[15] R. Tsien,et al. A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.
[16] B. Livett,et al. Biphasic Effect of Eserine and Other Acetylcholinesterase Inhibitors on the Nicotinic Response to Acetylcholine in Cultured Adrenal Chromaffin Cells , 1982, Journal of neurochemistry.
[17] S. Ito,et al. EXOCYTOTIC RELEASE OF CATECHOLAMINE FROM PERFUSED ADRENAL GLAND OF GUINEA‐PIG INDUCED BY VERATRIDINE , 1980, British journal of pharmacology.
[18] Y. Nakazato,et al. THE EFFECT OF VERATRIDINE ON THE RELEASE OF CATECHOLAMINES FROM THE PERFUSED ADRENAL GLAND , 1979, British journal of pharmacology.
[19] J. Hochman,et al. Catecholamine secretion by isolated adrenal cells. , 1976, Biochimica et biophysica acta.
[20] A. Maelicke,et al. A novel agonist binding site on nicotinic acetylcholine receptors. , 1993, Journal of receptor research.
[21] A. Kling,et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer??s type , 1987 .
[22] M. Ota,et al. Effects of veratrum alkaloids on membrane potential and conductance of squid and crayfish giant axons. , 1973, The Journal of pharmacology and experimental therapeutics.